Cure­Vac nabs a top No­var­tis sci­en­tist for CSO slot as mR­NA vac­cines seize the spot­light

One of the key play­ers in the race to de­vel­op a new mR­NA vac­cine to fight Covid-19 has reshuf­fled the top spots in the ex­ec­u­tive suite. And they’re bring­ing in a No­var­tis vet out of Har­vard to spear­head their work on mR­NA.

Cure­Vac, which just filed for an IPO that’s still tak­ing shape, has for­mal­ly hand­ed Franz-Wern­er Haas the CEO ti­tle, af­ter giv­ing it to him on an in­ter­im ba­sis. And the still rather stealthy Ger­man biotech large­ly owned by bil­lion­aire Di­et­mar Hopp has re­cruit­ed Ig­or Splaws­ki as its chief sci­en­tif­ic of­fi­cer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN